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Abstract
Background: Histone deacetylase inhibitors have been proposed as potential enhancers of the cytotoxic effect of 
cisplatin and other anticancer drugs. Their application would permit the use of lower therapeutic doses and reduction 
of the adverse side effects of the drugs. However, the molecular mechanisms by which they sensitize the cells towards 
anticancer drugs are not known in details, which is an obstacle in developing effective therapeutic protocols.
Results: In the present work, we studied the molecular mechanisms by which sodium butyrate sensitizes cancer cells 
towards cisplatin. HeLa cells were treated with 5 mM butyrate, with 8 μM cis-diaminedichloroplatinum II (cisplatin), or 
with both. Cells treated with both agents showed approximately two-fold increase of the mortality rate in comparison 
with cells treated with cisplatin only. Accordingly, the life span of albino mice transfected with Ehrlich ascites tumor 
was prolonged almost two-fold by treatment with cisplatin and butyrate in comparison with cisplatin alone. This 
showed that the observed synergism of cisplatin and butyrate was not limited to specific cell lines or in vitro protocols, 
but was also expressed in vivo during the process of tumor development. DNA labeling and fluorescence activated cell 
sorting experiments showed that cisplatin treatment inhibited DNA synthesis and arrested HeLa cells at the G1/S 
transition and early S phase of the cell cycle. Western blotting and chromatin immunoprecipitation revealed that this 
effect was accompanied with a decrease of histone H4 acetylation levels. Butyrate treatment initially reversed the effect 
of cisplatin by increasing the levels of histone H4 acetylation in euchromatin regions responsible for the G1/S phase 
transition and initiation of DNA synthesis. This abrogated the cisplatin imposed cell cycle arrest and the cells traversed 
S phase with damaged DNA. However, this effect was transient and continued only a few hours. The long-term effect of 
butyrate was a massive histone acetylation in both eu- and heterochromatin, inhibition of DNA replication and 
apoptosis.
Conclusion: The study presents evidence that cell sensitization towards cisplatin by sodium butyrate is due to 
hyperacetylation of histone H4 in specific chromatin regions, which temporarily abrogates the cisplatin imposed cell 
cycle arrest.
Background
Numerous reports in the recent years have described the
anticancer effect of histone deacetylase inhibitors [1-3].
For the time being, it does not seem probable that they
c o u l d  b e  u s e d  i n  c a n c e r  t h e r a p y  a l o n e ,  b u t  i n c r e a s i n g
body of evidence suggests that at least some could have a
future in combination with different anticancer agents [4-
6]. Sodium butyrate is the sodium salt of the butyric acid,
which is a four carbon normal fatty acid and is a natural
metabolite in many organisms including bacteria popu-
lating the gastrointestinal tract. Roles for butyrate have
been established in a number of epigenetically controlled
activities such as cell differentiation, proliferation, motil-
ity, induction of cell cycle arrest, apoptosis [7], and even
in memory formation [8]. However, the mechanisms by
which butyrate suppresses growth and induces cellular
differentiation or apoptosis are not known in details [9].
Microarray assays of global gene expression profiles have
shown that over 450 genes were significantly regulated by
butyrate in bovine kidney epithelial cells. Most of them
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were down-regulated, but over 30 genes were up-regu-
lated [10]. Among the down-regulated genes were genes
crucial for initiation of DNA synthesis such as MCM and
Orc proteins, which are essential for the assembly of the
prereplication complex. CDC2/Cdk1 and related cyclins
were also down-regulated. On the other hand, genes
related to apoptosis were up-regulated. In another assay
over 10,000 genes were found responsive to butyrate reg-
ulation in human epithelial cells [11]. Butyrate exerts sev-
eral modulatory effects on nuclear proteins and DNA
such as induction of histone acetylation and phosphory-
lation, and hypermethylation of cytosine residues in DNA
[12]. The steady state of histone acetylation is controlled
by the equilibrium of two distinct families of enzymes,
histone acetyltransferases (HATs) and histone deacety-
lases (HDACs). Since the early discovery of histone acety-
lation by Allfrey and colleagues [13], this
posttranslational modification has been correlated with
the processes of chromatin assembly and transcription
[14]. At present, it is well established that actively
expressed genes are associated with hyperacetylated core
histones, while repressed genes are associated with
hypoacetylated histones [15]. Activation and repression
of different genes is achieved by changes of chromatin
structure. Acetylation of core histones at specific lysine
residues in the NH2 -terminal tails leads to relaxation of
the compact chromatin structure allowing transcriptional
activators to access DNA [16]. In addition, core histones
associated with DNA replication origins are hypoacety-
lated when the origins are inactive but undergo hyper-
acetylation before their firing [17,18]. Core histone
acetylation and deacetylation are also associated with
checkpoint activation and repression [19]. However,
recent reports have suggested that the relationship of
chromatin function and histone acetylation could be
more complex than the simple scheme in which acetyla-
tion means activity and deacetylation means inactivity. It
has been shown that not the acetylation status, but rather
acetylation turnover, which could be very rapid, is impor-
tant [16,20]. This might explain the results of microarray
assays in which butyrate treatment, which caused global
and permanent histone acetylation actually brought
about repression of most of the genes assayed.
In the present paper, we have studied the sensitizing
effect of the HDAC inhibitor sodium butyrate on HeLa
cells towards cisplatin treatment. We have found that cis-
platin arrested HeLa cells at the G1/S phase boundary
and early S phase of the cell cycle and that this arrest was
accompanied with reduction of histone H4 acetylation in
chromatin. Butyrate treatment initially reversed the cispl-
atin-induced deacetylation of histone H4 in chromatin
regions responsible for DNA synthesis, which led to abro-
gation of the cell cycle arrest. Thus by forcing the cells to
traverse the S phase of the cell cycle with damaged DNA,
butyrate enhanced the lethal effect of cisplatin. At later
times butyrate treatment brought about massive hyper-
acetylation of total chromatin histone H4 and probably of
all core histones and cessation of DNA synthesis.
Results
Synergistic effect of butyrate and cisplatin on HeLa cells 
death rates
The first experiments we carried out were to establish the
synergistic effect of butyrate and cisplatin on tumor cells.
To follow the kinetics of cell survival we treated exponen-
tially growing HeLa cells with 5 mM butyrate, with 8 μM
cisplatin and with a combination of both agents. One, 2
and 3 days later cells were stained with trypan blue to
mark the dead cells, and the viable cells were counted.
The results showed that the cells treated with butyrate
gradually stop to proliferate during the first day and in the
course of the next 3 days about 20% of them died. This
result is in agreement with the literature data that
butyrate depletes cellular populations of S-phase cells
and causes apoptosis [21]. Nevertheless, at day 1, almost
all cells were alive and over 75% of them remained alive in
the course of the following 3-day period. On the contrary,
cells treated with cisplatin began to die from the very
beginning in a time dependent way and at day 1 about
30% (p ≤ 0.01) of them were dead. Treatment with both
agents simultaneously showed that butyrate and cisplatin
had synergistic effect. In this case, over 60% (p ≤ 0.0005)
of the cells were dead at day 1 (Fig.1).
Synergistic effect of butyrate and cisplatin in vivo
Next, we showed that the observed synergism was not
limited to a specific cell line or in vitro protocol, but was
also expressed in vivo during the process of tumor devel-
Figure 1 HeLa cells mortality rates . Exponentially growing HeLa 
cells were treated with 8 μM cisplatin, with 5 mM butyrate, or with 
both. At days 1, 2 and 3 after the treatment, cells were collected, 
stained with trypan blue and counted. The numbers of viable cells 
were expressed as percentage of the number of control cells at day 1. 
The results are means of three independent experiments and standard 
deviations are shown with error bars.Koprinarova et al. BMC Molecular Biology 2010, 11:49
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opment. To this end, we used Ehrlich-Lettre hyperdiploid
ascites tumor (EAT). Albino mice were transfected with
the tumor by an intraperitoneal injection of undiluted
ascites liquid. The tumor cells rapidly proliferated in the
abdominal cavity increasing the tumor volume and the
animals died 10-11 days after the inoculation. This makes
EAT a suitable model for rapid, preliminary assessment of
the anticancer effect of different agents [22-24]. We inoc-
ulated three groups of mice, each consisting of 5 animals,
with EAT. Twenty four hours later, they received 5 mg/kg
cisplatin, or 166 mg/kg butyrate, or both by a single intra-
peritoneal injection. T he time of dea t h of each animal
was recorded. The control animals died 9 to 13 days after
transfection with EAT, as expected. Cisplatin treatment
led to 1-2 days increase of the life span of the mice (not
statistically significant). Butyrate treatment in the applied
concentration prolonged the life span of the transfected
animals with approximately 3 days (not statistically sig-
nificant). In agreement with the results with HeLa cells,
combined treatment with cisplatin and butyrate almost
doubled (statistically significant) the survival period of
EAT transfected mice (p = 0.0019), showing that in vivo
butyrate also enhances the cytotoxic effect of cisplatin on
tumor cells as it does in vitro (Table 1).
Effect of cisplatin and butyrate on the cell cycle
After having established that butyrate enhances the cyto-
toxic effect of cisplatin both in vitro and in vivo, we inves-
tigated the molecular mechanisms underlying this
synergism. It should be noted, that although cisplatin is
widely used and for a long time, the precise mechanisms
of its cytotoxicity remain unknown. Its main target is
DNA where it produces mostly intrastrand bridges that
are located in the major groove of the DNA double helix
and block transcription and DNA replication. There are
data that cisplatin treatment causes G1 and S phase cell
cycle arrest, during which cells repair the cisplatin-
induced damage [25,26]. Further, it was shown that retin-
oblastoma protein (Rb) deficiency could abrogate the cis-
platin induced cell cycle arrest, the bypass resulting in
increased sensitivity to the drug both in cell cultures and
xenograft models [27,28]. Rb has diverse functions in the
cell cycle progression and differentiation. Its major role is
to recruit histone deacetylases to the E2F target genes
responsible for the G1/S phase transition thus keeping
them suppressed and maintaining the G1 status. In this
way, histone deacetylation correlates with repression of
E2F target genes and G1/S arrest, while histone acetyla-
tion is connected with S phase progression. For this rea-
s o n ,  w e  p r e s u m e d  t h a t  e f f e c t  s i m i l a r  t o  t h a t  o f  R b
inactivation could be achieved with HADC inhibition
since the result of both treatments would be acetylation
of histones in the vicinity of the E2F binding sites, abroga-
tion of the cisplatin induced arrest and S phase transition.
To check this possibility we studied the effect of cisplatin
and butyrate on the cell cycle. Exponentially growing
HeLa cells were treated with 8 μM cisplatin, with 5 mM
sodium-butyrate, or with both for 24 hours and the cell
cycle distribution was determined by flow cytometry.
Our results showed that exponentially growing HeLa
cells had the following cell cycle distribution: 60% in G1,
20% in S and 18% in G2/M phases. In agreement with the
literature data [29,30], cells treated with butyrate for 24
hours were blocked mostly in G1 but also in G2 phases
and were depleted of S-phase cells. Cells treated with cis-
platin were blocked at the G1/S boundary and early S
phase of the cell cycle with only 2-3% being in G2 phase.
In addition, certain amount of sub-G1 phase material was
present indicating that part of the cells have undergone
apoptosis. The cell cycle distribution profiles of HeLa
cells treated with cisplatin and butyrate differed from that
of cells treated with cisplatin in two aspects. First, the
amount of the sub-G1 material, indicative for apoptosis,
has increased. This result confirmed the results from the
survival experiments (Fig. 1) showing the synergistic
effect of cisplatin and butyrate. Second, the S phase frac-
Table 1: Survival of mice tranfected with EAT and treated with butyrate, cisplatin and both.
Treatment Life-span (days)*  T/C**  P #
Controls 10.8 ± 2.0 1
Butyrate 14.0 ± 4.5 1.3 0.19
Cisplatin 12.0 ± 3.5 1.1 0.53
Cisplatin + Butyrate 19.0 ± 3.4 1.8 0.0019
* Albino mice were injected intraperitoneally with undiluted EAT liquid (day 0). After 24 hours (day 1) groups of five animals received another 
intraperitoneal injection with cisplatin, butyrate or both. Mean life spans and the standard deviations are shown.
** The ratio between the mean life spans of the treated animals (T) and the controls (C).
# The probability between control and experimental groups assuming null hypothesis.Koprinarova et al. BMC Molecular Biology 2010, 11:49
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tion was decreased while the G2 phase fraction was sig-
nificantly increased to 17-18% (p ≤ 0.005), which showed
that butyrate had relieved the cisplatin induced cell cycle
arrest and part of the cells have traversed the S phase with
damaged DNA (Fig. 2).
Effect of cisplatin and butyrate on DNA synthesis
To follow the butyrate induced S phase transition, we
studied the effect of cisplatin and butyrate on DNA syn-
thesis in the course of the first several hours after the
treatment. We treated exponentially growing HeLa cells
with 8 μM cispaltin, with 5 mM butyrate, or with both. At
2 hours intervals aliquots were withdrawn, 1 μCi/mL of
3H-thymidine was added and 30 min later, cells were col-
lected, washed and counted. Our results showed that
butyrate alone had initial positive effect on DNA synthe-
sis.  3H-thymidine incorporation of HeLa cells treated
with butyrate increased at the 4th hour by about 10-15%,
after which began to decrease. Other authors have also
reported an initial increase of the S phase cell population,
followed by inhibition of proliferation [21]. A possible
explanation could be that due to the relaxation of chro-
matin structure caused by the hyperacetylation of core
histones, additional replication origins were activated.
On the other hand, cisplatin began to inhibit DNA syn-
thesis almost immediately and at the 6th hour the 3H thy-
midine incorporation decreased by over 50% (p ≤ 0.0025).
In a previous paper, we have shown that the initial inhibi-
tion of DNA synthesis by cisplatin was a result of S phase
arrest due to blocked DNA elongation of the already initi-
ated DNA chains [31]. Nevertheless, the 3H thymidine
incorporation continued for several hours due to the con-
tinuous entry of G1 cells into S phase and the subsequent
activation of new replication origins. However, after 12
hours, DNA synthesis was completely inhibited, which
showed that at this time G1 phase arrest had also been
established and both elongation of the already initiated
DNA strands and the initiation of new DNA strands had
been blocked. The simultaneous treatment of the cells
with cisplatin and butyrate had an effect that was a com-
bination of the effects of the two agents and in this case,
the  3H thymidine incorporation increased between the
4th and the 6th hours by 12-15% (p ≤ 0.11) in comparison
with the cells treated with cisplatin only. A conclusion
can be drawn that butyrate relieved the cisplatin imposed
block on DNA synthesis and temporarily permitted the
damaged cells to traverse the S phase. For this reason, the
cells treated with the two agents showed higher levels of
DNA synthesis than the cells treated with cisplatin only
(Fig. 3). We supposed that the observed cisplatin induced
arrest could be caused by deacetylation of core histones
and that butyrate, which is a potent HDACs inhibitor,
prevented deacetylation thus permitting the cells to enter
and traverse the S phase. However, this effect was tempo-
rary and 12 hours later in all three cases, i.e. cisplatin,
butyrate and cisplatin plus butyrate, DNA synthesis was
inhibited (Fig. 3).
Effect of cisplatin and butyrate on total histone H4 
acetylation
To shed more light on the effect of cisplatin and butyrate
on histone H4 acetylation we used Western blotting.
Exponentially growing HeLa cells were treated with 5
mM butyrate, 8 μM cisplatin or both for 4 and 24 hours
Figure 2 FACS analysis of HeLa cells . HeLa cells were treated with 8 
μM cisplatin, with 5 mM butyrate, or with both. Twenty four hours after 
the treatment cells were fixed, stained with propidium iodide and 2 × 
104 cells were subjected to FACS analysis.
Figure 3 DNA synthesis in HeLa cells . HeLa cells were treated with 
8 μM cisplatin, with 5 mM butyrate, or with both. At the specified times 
aliquots were withdrawn, 1 μCi/mL of 3H-thymidine was added and 30 
min later the cells were collected, washed and counted. 3H incorpora-
tion was expressed as percentage of the control. The results are means 
of three independent experiments and standard deviations are shown 
with error bars.Koprinarova et al. BMC Molecular Biology 2010, 11:49
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and equal amounts of histones were subjected to SDS-
polyacrylamide gel electrophoresis. They were trans-
ferred onto nitrocellulose membrane and acetylated his-
tone H4 was determined with an antibody against
acetylated histone H4. Our results showed that when
HeLa cell were treated with butyrate for 4 hours, total
histone H4 acetylation increased by approximately 30% (p
≤ 0.16). Treatment with cisplatin decreased the acetyla-
tion level of histone H4 in comparison with the control by
30-40% (p ≤ 0.093). The combined treatment with cispla-
tin and butyrate increased the acetylation level of histone
H4, which was an indication that butyrate overruled the
cisplatin imposed block on histone H4 acetylation. When
the cells were treated as above, but for 24 hours, the
results were in the same direction with the only differ-
ence that the acetylation levels of histone H4 in butyrate
treated cells were 2-3 times higher than in the cells
treated with the respective agents for 4 h only (Fig. 4A,
B). A conclusion can be drawn that butyrate treatment
brings about a gradual acetylation of histone H4, which
continues for many hours and probably depends on the
chromatin structure. It seems plausible to assume, that
upon inhibition of histone deacetylases, acetylation of
histone H4 first occurs at chromatin regions with more
relaxed structure such as euchromatin where HATs are
already present, or have easy access. This hyperacetyla-
tion of the euchromatin regions would abrogate the cispl-
atin induced cell cycle arrest and was probably the reason
for the observed enhancment of DNA synthesis in the
first hours of butyrate treatment (Fig. 3). At later times,
acetylation of histone H4 in heterochromatin also takes
place and this was probably connected with the G1 and
G2 phases arrest and apoptosis.
Effect of cisplatin and butyrate on acetylation of histone H4 
at specific chromatin regions
To check this hypothesis the acetylation of histone H4 at
specific chromatin regions was studied by chromatin
immunoprecipitation. HeLa cells were treated with
butyrate, cisplatin and both for 4 and 24 hours. The cells
were crosslinked with formaldehyde and sonicated on ice
to obtain DNA fragments with average length of 300-500
bp. Aliquots were withdrawn for input DNA preparations
and the rest of the samples were immunoprecipitated
with anti-acetylated histone H4 antibody. Equal amounts
of immunoprecipitated (ChIP) and control (Input) DNA
were used as templates to amplify four DNA sequences.
Two of the sequences were within the euchromatic c-myc
region - from the early replicating c-myc origin of DNA
replication and the actively transcribed c-myc gene,
respectively. The other two sequences were within the
nontranscribed β-globin region and were from the late
replicating β-globin origin of replication and the nontran-
scribed globin G gene (Fig. 5A). These sequences are
located in heterochromatin [17,21,32]. In agreement with
our previous results [18], in control cells both the c-myc
origin and the c-myc gene showed higher levels of histone
H4 acetylation than the late replicating β-globin replica-
tion origin and the nontranscribed globin G gene.
Butyrate treatment for 4 hours did not significantly
change this picture probably because histone H4 in the
vicinity of the c-myc origin and the c-myc gene was
already acetylated, while the treatment period of 4 hours
was not sufficient to induce acetylation of histone H4 in
heterochromatin. Cisplatin treatment for 4 hours
decreased histone H4 acetylation by 30% to 70% in all
four chromatin regions (Fig. 5C). Since this coincided
with the inhibition of the DNA synthesis, a conclusion
Figure 4 Western blotting of acetylated histone H4 . HeLa cells 
were treated with 8 μM cisplatin, with 5 mM butyrate, or with both. 
Four and 24 hours after the treatment aliquots were withdrawn, total 
histone fraction was isolated and equal amount of histones were sub-
jected to SDS-polyacrylamide gel electrophoresis. (A) The proteins 
were transferred onto nitrocellulose membranes and stained with 
anti-acetylated histone H4 antibody. Ponceau S staining of H4 is shown 
as loading control. (B) The acetylated histone H4 was visualized and 
quantified by the Odyssey scanning system. The acetylation levels are 
expressed as percentage of the untreated control. The results are 
means of five independent experiments and standard deviations are 
shown by error bars.Koprinarova et al. BMC Molecular Biology 2010, 11:49
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Figure 5 Acetylation status of chromatin at four DNA sequences: c-myc ori, c-myc gene, β-globin ori and G-globin gene, upon treatment 
with cisplatin and butyrate . (A) Map of the human c-myc and β-globin loci. The positions of the origins of replication zones (replicators) are shown 
by solid lines and the genes are shown by arrows. The four sequence-tagged sites (STSs) amplified by PCR are designated as c-myc ori and c-myc gene 
and β-globin ori and G-globin gene and shown with vertical lines. (B) HeLa cells were treated with 8 μM cisplatin, with 5 mM butyrate, or with both 
and 4 h or 24 h after the treatment, chromatin was immunoprecipitated with anti-acetylated histone H4 antibody. Aliquots from the immunoprecip-
itated (ChIP) and input (Input) DNA were subjected to PCR using primers for the respective DNA sequences. The PCR products were separated on 2.5% 
agarose gels and stained with ethidium bromide. (C) The DNA fractions were scanned and quantified and the ratios ChIP/Input for the four sequences 
after the different treatments were shown. Results are means of three independent experiments and the standard deviations are shown with error 
bars.Koprinarova et al. BMC Molecular Biology 2010, 11:49
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could be drawn that the cisplatin imposed cell cycle arrest
was associated with deacetylation of histone H4. This
conclusion is in agreement with the experiments
described in an earlier paper [19] in which we have
reported that UV light induced cell cycle arrest was also
accompanied with a decrease of histone H4 acetylation.
When butyrate was applied simultaneously with cisplatin,
it restored the acetylation levels of histone H4 to those of
control cells, which led to abrogation of the cell cycle
arrest, resumption of the DNA synthesis and transition
through the S phase (Figs. 2, 3). When the same experi-
ments were carried out for 24 hours, butyrate treated
cells showed higher histone H4 acetylation in the hetero-
chromatic β-globin replication origin and the nontran-
s cri bed  g l o b i n  G  g e n e  bo t h  i n  t h e  a bs e n c e  a n d  i n  t h e
presence of cisplatin (Fig. 5C). This indicated that at this
time hetrochromatin was also acetylated in addition to
euchromatin, which was probably the reason for the
observed inhibition of DNA synthesis and cell cycle
arrest (Figs. 2, 3).
Discussion
Cisplatin is an effective chemotherapeutic agent against a
number of cancers such as head and neck cancer. Never-
theless, it exhibits two major drawbacks that limit its
application in cancer therapy. These are its severe side
effects and the rapid development of drug resistance [33].
They are mutually connected because the adverse side
effects do not permit the application of high enough
doses and on the other hand, under-dosing leads to devel-
opment of resistance of the cancer cells. For this reason,
drugs that sensitize cancer cells towards cisplatin could
increase its therapeutic efficacy. Butyrate and other
HDAC inhibitors have shown such potential, but we still
do not know the molecular mechanisms of this sensitiza-
tion, which is an obstacle in designing effective therapeu-
tic procedures. Here we have analyzed the mechanism by
which butyrate sensitizes HeLa cells towards the action of
cisplatin. We examined the effects of butyrate and cispla-
tin on DNA replication and on the acetylation of histone
H4 in eu- and heterochromatin. Our results showed that
cisplatin treatment inhibited DNA synthesis and arrested
HeLa cells at the G1/S transition and early S phase of the
cell cycle. This effect was accompanied with hypoacetyla-
tion of the core histone H4 in both eu- and heterochro-
matin. On the other hand, butyrate exhibited two
different effects on HeLa cells, which could be arbitrarily
designated as short-term and long-term effects. The
short-term effect, which occurred during the first 4-6
hours, was characterized by hyperacetylation of histone
H4 and probably of other core histones in euchromatin
regions associated with specific DNA sequences respon-
sible for the G1/S phase transition and DNA replication.
This effect overruled the cisplatin imposed block on
DNA replication and the cells traversed the S phase with
damaged DNA. Due to this effect in the early hours of its
application, butyrate enhanced the cisplatin cytotoxic
effect. During the second phase, butyrate caused indis-
criminate hyperacetylation of core histones including
those in heterochromatin, and probably other proteins,
which led to inhibition of DNA synthesis, down-regula-
tion of genes connected with cell cycle progression and
triggered apoptosis. These results are in agreement with
other reports showing that the effect of butyrate is time
dependent. It has been shown that in the first hours after
butyrate treatment cellular histone deacetylases are
inhibited, core histones are hyperacetylated and many
genes that have been repressed are activated. Later on
irreversible changes connected with the expression of
p21, Rb, Id1 and other regulatory genes take place leading
to cell cycle arrest in G1 and G0, to terminal differentia-
tion and finally to apoptosis [4,21].
The approach to sensitize cells towards the action of
anticancer drugs by abrogation of the cell cycle check-
points has already been applied - by inhibition or knock
down of the checkpoint kinases Chk1, Chk2, or MK2 [34-
36]. Other authors have tried to knock out, or knock
down key regulatory proteins such as Rb, p53, p21, etc
[27,28]. The knock out of Rb leads to a 2-fold increase of
the lethal effect of cisplatin both in vivo and in vitro. Rb is
a crucial player in the G1 state maintenance by prevent-
ing hyperacetylation of core histones at genes important
for DNA replication. Its absence or inactivation permits
their acetylation and ensures the G1/S transition. Our
results are in agreement with these findings showing that
the acetylation status of the core histones is important for
cell cycle signaling. Thus, it seems logical to suggest that
the mechanism by which butyrate, a potent HDAC inhib-
itor, sensitized the cells towards cisplatin was associated
with hyperacetylation of core histones and abrogation of
the cisplatin imposed cell cycle arrest.
The data presented here underlie both the importance
of timing and the limitations of the combined application
of cisplatin and butyrate in cancer treatment. Our results
are in agreement with the finding that when butyrate is
applied simultaneously with, or after cisplatin, the syner-
gistic effect is stronger than when butyrate is applied first
[6]. They also show that there is a specific a few hours
window after butyrate administration during which it
could sensitize the cells towards the action of cisplatin
and that outside this window, butyrate would have little
or no effect as enhancer.
Conclusions
In this paper, we investigated the molecular mechanisms
through which butyrate sensitized cells towards cisplatin.
We showed that cisplatin arrests HeLa cells at the G1/S
transition and early S phase, which is accompanied withKoprinarova et al. BMC Molecular Biology 2010, 11:49
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reduction of histone H4 acetylation. Initially butyrate
reverses this effect and by increasing histone H4 acetyla-
tion in euchromatin regions permits the cells to traverse S
phase with damaged DNA. This increased the cell mor-
tality thus enhancing the cytotoxic effect of cisplatin.
Later, butyrate itself caused a G1 phase arrest and its syn-
ergistic effect decreased. This finding indicates both the
importance of timing and the limitations of the combined
application of cisplatin and butyrate in cancer treatment.
A conclusion is drawn that i) butyrate can enhance the
cytotoxic effect of cisplatin only if applied simultane-
ously, or shortly after it, and ii) the period during which
butyrate enhances cisplatin cytotoxicity is limited to the
first few hours of its application.
Methods
Cells and treatment
Human HeLa cells (obtained from the American Type
Culture Collection) were cultured in monolayer in D-
MEM with 10% foetal bovine serum supplemented with
antibiotics in 5% CO2 atmosphere. The cell cycle distribu-
tion was determined by fluorescence activated cell sort-
ing (FACS) analysis. The cells were washed with
phosphate buffered saline (PBS), pH 7.4, fixed in 70% eth-
anol overnight and collected by centrifugation at 1000 × g
for 10 min. They were resuspended in PBS, treated with
20 μg/mL RNase for 30 min at 37°C and stained with 20
μg/mL propidium iodide at room temperature for 90 min.
2 × 104 cells/sample were analyzed with a Becton Dickin-
son (Facscalibur) cell sorter, using CellQuest software
(Becton Dickinson).
Fresh stock solutions of 1 mg/mL of cis-diaminedichlo-
roplatinum II (cisplatin) (Sopharma, Sofia, Bulgaria) in
PBS and 1 M sodium butyrate were added to the cell cul-
tures to the desired final concentrations and the cells
were further cultured for the specified periods. For label-
ing of DNA, 3H-thymidine with specific radioactivity of
37 MBq/mL (GE Healthcare, Amersham) was used. After
the labeling period, cells were washed with PBS, precipi-
tated in ice-cold 15% trichloroacetyc acid (TCA), retained
on glass fiber filters (GF/C, Millipore), washed with ice-
cold 5% TCA and counted with a Beckmann LS 1801
scintillation counter. Death cells were determined after
staining with 1% Trypan blue for 10 min.
Animal model
Three month-old ICR albino mice weighing 20 g were
injected intraperitoneally with 0.3 mL (107 cells) undi-
luted ascites liquid of Ehrlich-Lettre hyperdiploid ascites
tumor. 24 hours later groups of 5 animals received intrap-
eritoneally either 5 mg/kg (100 μl of stock solution con-
taining 1 mg/mL cisplatin in PBS) cisplatin, or 166 mg/kg
(100 μl of 0.3 M stock solution of sodium butyrate in 0.14
M NaCl) sodium butyrate, or both. Mice were kept on
standard laboratory diet. The time of death of each ani-
mal was recorded and the mean life spans and the stan-
dard deviations were calculated. Differences between
control group and the experimental groups were esti-
mated using Student's t test. A probability level of 0.05
was chosen for statistical significance. The experiments
were performed in accordance with the guide for Care
and Use of Laboratory Animals, a work permission
№11130007 of the Institute of Experimental Pathology
and Parasitology, Bulgarian Academy of Sciences.
Chromatin immunoprecipitation
HeLa cells were crosslinked with formaldehyde and then
sonicated with Branson sonifier cell disrupter, 70% duty
cycle, 15 s pulses, 3 pulses with 1 min intervals between
pulses, on ice, to obtain DNA fragments with average
length of 200-500 bp. Aliquots were withdrawn for input
DNA preparations and the rest of the samples were
immunoprecipitated with anti-acetylated histone H4
antibody kit (Upstate Biotech) as recommended by the
manufacturer. Formaldehyde crosslinks were removed at
65°C for 4 hours and DNA was isolated by phenol/chloro-
form extraction and ethanol precipitation.
PCR and gel electrophoresis
The DNA sequences were amplified by 33 PCR cycles
using the following primers: c-myc-ori (1829-1891) for-
ward: CGCGCCCATTAATACCCTT, reverse: AGGGC-
CGCGCTTTGA; c-myc gene (4488-4552) forward:
TTGTGTGCCCCGCTCC, reverse: TTCCTGTTGGT-
GAAGCTAA; globin-G gene (33029-133107) forward:
TTTAACTTCCAAAGAACAAGTGC, reverse: GCG-
GCTAAAAGACCAGA; β-globin ori (62073-62147) for-
ward: CAGGAGCAGGGAGGGCAGGA, reverse: GAA
GCAAATGTAAGCAATAGATGG. The numbers in the
brackets indicate the positions of the corresponding
sequence-tagged sites (STS) in GenBank [17]. The PCR
products were run on 2.5% agarose gels and stained with
ethidium bromide. Gels were scanned and quantified
with Gel-Pro Analyzer 3.1 software.
Western blotting
Cells were washed twice with PBS, lysed in 0.5% TritonX-
100 in PBS and the crude nuclear fraction recovered by
centrifugation. Total histone was isolated by extraction
with 0.2 N HCl for 2 hours in the cold. Protein concentra-
tions were determined spectrophotometrically at 280 nm
and 20 μg of protein of each sample were fractionated by
15% SDS-polyacrylamide gel electrophoresis. Histones
were transferred to nitrocellulose Hybond-C membrane
(GE Healthcare, Amersham) using Towbin transfer buffer
(25 mM Tris-HCl, 192 mM glycine pH 8.6, 20% metha-
nol, 1% SDS). After blocking in Odyssey blocking buffer
(LI-COR Biosciences), the membranes were incubated
with rabbit antibody to acetylated H4 (Upstate, dilutedKoprinarova et al. BMC Molecular Biology 2010, 11:49
http://www.biomedcentral.com/1471-2199/11/49
Page 9 of 9
1:2000), washed with TBS (50 mM Tris-HCl, 150 mM
NaCl, pH 7.4) containing 0.01% Tween 20, incubated with
Odyssey goat anti-rabbit secondary antibody (LI-COR
Biosciences), washed with TBS with 0.01% Tween 20, and
visualized and quantified by the Odyssey scanning sys-
tem. Membranes were stained with Ponceau S to deter-
mine the amount of histone H4.
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